Teva Pharmaceutical Industries (TEVA) Share-based Compensation (2016 - 2025)
Historic Share-based Compensation for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $51.0 million.
- Teva Pharmaceutical Industries' Share-based Compensation rose 5000.0% to $51.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $157.0 million, marking a year-over-year increase of 2764.23%. This contributed to the annual value of $157.0 million for FY2025, which is 2764.23% up from last year.
- Per Teva Pharmaceutical Industries' latest filing, its Share-based Compensation stood at $51.0 million for Q4 2025, which was up 5000.0% from $34.0 million recorded in Q3 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Share-based Compensation registered a high of $51.0 million during Q4 2025, and its lowest value of $24.0 million during Q1 2022.
- For the 5-year period, Teva Pharmaceutical Industries' Share-based Compensation averaged around $32.2 million, with its median value being $31.5 million (2021).
- In the last 5 years, Teva Pharmaceutical Industries' Share-based Compensation plummeted by 2307.69% in 2023 and then surged by 5000.0% in 2025.
- Teva Pharmaceutical Industries' Share-based Compensation (Quarter) stood at $33.0 million in 2021, then grew by 9.09% to $36.0 million in 2022, then fell by 22.22% to $28.0 million in 2023, then grew by 21.43% to $34.0 million in 2024, then surged by 50.0% to $51.0 million in 2025.
- Its Share-based Compensation stands at $51.0 million for Q4 2025, versus $34.0 million for Q3 2025 and $38.0 million for Q2 2025.